CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CMSC
-0.0200
The Fort Worth Press - CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
USD
-
AED 3.672499
AFN 64.999712
ALL 79.73251
AMD 363.440013
ANG 1.790365
AOA 917.999834
ARS 1510.742703
AUD 1.407143
AWG 1.8025
AZN 1.69771
BAM 1.705151
BBD 2.014743
BDT 122.842733
BGN 1.683441
BHD 0.377072
BIF 3007.563373
BMD 1
BND 1.278286
BOB 9.828548
BRL 5.165749
BSD 1.000371
BTN 95.852241
BWP 13.566297
BYN 3.025994
BYR 19600
BZD 2.011918
CAD 1.401205
CDF 2310.999863
CHF 0.824195
CLF 0.024334
CLP 960.839822
CNY 6.70755
CNH 6.700875
COP 3214.45
CRC 447.525011
CUC 1
CUP 26.5
CVE 96.136744
CZK 21.265993
DJF 178.140476
DKK 6.52217
DOP 59.042263
DZD 133.863989
EGP 52.123098
ERN 15
ETB 163.400976
EUR 0.87249
FJD 2.218802
FKP 0.749304
GBP 0.748525
GEL 2.602537
GGP 0.749304
GHS 11.524327
GIP 0.749304
GMD 73.505413
GNF 8794.552556
GTQ 7.633994
GYD 209.29239
HKD 7.845735
HNL 26.85435
HRK 6.573196
HTG 130.743913
HUF 318.227971
IDR 17835
ILS 3.03663
IMP 0.749304
INR 95.99815
IQD 1310.490638
IRR 1374600.000262
ISK 121.450236
JEP 0.749304
JMD 157.960584
JOD 0.708989
JPY 157.249501
KES 129.497294
KGS 87.449711
KHR 4054.195438
KMF 428.000147
KPW 900.000318
KRW 1389.179589
KWD 0.30833
KYD 0.833682
KZT 447.238218
LAK 22416.551508
LBP 89581.983757
LKR 331.11734
LRD 173.066192
LSL 16.263563
LTL 2.95274
LVL 0.60489
LYD 6.354188
MAD 9.478186
MDL 17.581258
MGA 4336.662409
MKD 53.645926
MMK 2099.69268
MNT 3599.361607
MOP 8.083211
MRU 40.24412
MUR 47.569607
MVR 15.449545
MWK 1734.672526
MXN 17.251275
MYR 4.083699
MZN 63.909734
NAD 16.263705
NGN 1331.620095
NIO 36.809228
NOK 9.437485
NPR 153.367772
NZD 1.75219
OMR 0.384518
PAB 1.000379
PEN 3.37569
PGK 4.45264
PHP 62.999501
PKR 277.27411
PLN 3.80914
PYG 5930.433797
QAR 3.65652
RON 4.593504
RSD 102.388995
RUB 84.202169
RWF 1469.536863
SAR 3.726614
SBD 8.000512
SCR 13.927029
SDG 601.507612
SEK 9.87196
SGD 1.278198
SHP 0.747524
SLE 24.649771
SLL 20969.491881
SOS 571.677674
SRD 37.746499
STD 20697.981008
STN 21.360535
SVC 8.753575
SYP 13002.000254
SZL 16.258419
THB 33.365949
TJS 9.228308
TMT 3.51
TND 2.942646
TOP 2.40776
TRY 48.785098
TTD 6.790907
TWD 31.80103
TZS 2649.995975
UAH 44.694758
UGX 3945.963147
UYU 40.228081
UZS 11844.198871
VES 847.485102
VND 26022
VUV 118.29149
WST 2.754822
XAF 572.315643
XAG 0.015072
XAU 0.00023
XCD 2.70255
XCG 1.802885
XDR 0.707052
XOF 572.315643
XPF 103.976042
YER 236.550044
ZAR 16.31289
ZMK 9001.187957
ZMW 19.662326
ZWL 321.999592
SSP 5664.022588
MXV 1.955812
- Crisis-wracked Volkswagen warns of 10-bn-euro hit to profits
- New France boss Zidane confirms Mbappe as captain after naming first squad
- Costa Rica's Grynspan tops third informal poll for UN chief: diplomat
- California governor signs order to explore AI 'kill switch'
- Stock markets retreat after central bank rate hikes
- Head leads run spree as Australia win Zimbabwe ODI series
- Russia labels director of Cannes Grand Prix winner a 'foreign agent'
- In-form Raphinha wants to finish career at Barcelona
- Macron warns of Russian 'hybrid' threat after meeting presidential hopefuls
- Warren Buffett steps down as Berkshire Hathaway chairman
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.
CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of "0" or "1" and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. This pivotal step underscores CAGE Bio's commitment to addressing the unmet needs of patients with moderate to severe AD and low body surface area (BSA) involvement, where treatment speed and efficacy must be balanced with the cost of systemic exposure and side effects.
"CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects" said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.
"Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the Phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated," said Nitin Joshi, Ph.D., CEO of CAGE Bio.
Atopic dermatitis is a chronic inflammatory skin condition affecting millions globally. Patients with highly localized, moderate to severe symptoms face limited treatment options. CGB-500 seeks to fill this gap, offering a high efficacy alternative with dramatically lower systemic exposure.
CAGE Bio remains committed to advancing clinical programs that deliver transformative therapies (efficacy of a biologic with safety of a topical ) for immuno-dermatological disorders.
About CAGE Bio
CAGE Bio is a clinical-stage biotechnology company developing innovative localized therapies for immune-mediated dermatological conditions. Its proprietary ionic liquid technology ensures effective drug delivery to target areas with minimal systemic exposure, improving patient outcomes.
Phone: +1 (650) 996-1845
email. [email protected]
SOURCE: CAGE Bio Inc.
D.Ford--TFWP
